Optimizing Patient Selection & Standardizing the Dose, Scheduling & Response Analysis; Targeting TLR9 in High-Risk Resectable Melanoma & Neoadjuvant CMP-001 & Nivolumab

Time: 9:30 am
day: Day Two

Details:

  • Assessing the use of historical markers and the need for further exploration
  • Understanding the design, translation and execution in response assessments

Speakers: